ODIX

Founded in October 2020, Odix Medical s.a. is a Belgian start-up active in the orthopedic rehabilitation devices market. Our three founders, Valérie Gordenne, CEO, Francis Frankenne, CTO, and Xavier Delcorps, CCO, accumulate globally more than 75 years of experience in pharma and medical device industries. Their previous executive positions in R&D and business development allowed them to master the necessary skills to start this exciting journey. In 2022, the team was completed by our project leader, Sophie Deflandre, freshly graduated in biomedical engineering at Uliege and entrepreneurship at HEC-Liège.  

At Odix, we envision our future as becoming an international reference in orthopedic rehabilitation, targeting the most impactful disorders. Our first project, Lumbacure®, focuses on Low Back Pain (LBP). This pathology is a global burden, bound to increase in future years due to our sedentary lifestyle and the aging population. Associated with stress, disability and absence from work, LBP reduces productivity and affects more higher-income countries. The prevalence of this pathology can go up to 20% and peaks in the elderly population, making it one of the leading causes of disability worldwide. 

Our target audiences answer this global need for an improved LBP rehabilitation. In addition to rehabilitation centers and private therapists, we also target fitness centers, occupational therapy, company prevention, geriatric care and retirement homes. We aim to deliver our solution to everyone needing it.   

To deliver an innovative device sourced from the latest academic research, we partner in our journey with international KOLs, experts in the domain of orthopedic rehabilitation, such as Professor Deborah Falla (University of Birmingham, UK), Professor Wim Dankaerts (KU Leuven, Belgium), Professor Christophe Demoulin (Uliège, Belgium), and Professor Catherine Disselhorst-Klug (Aachen University, Germany).  Our team combines both experienced managers and freshly graduated talents with the latest innovative knowledge in various domains. 

Lumbacure® is still in a proof-of-concept phase with on-going pilot studies. 2024 is a pivotal year of capital increase to reach the market in 2027. In Europe, the commercialization of our medical device will be organized through specialized distributors. Moreover, the US market will be reached through strong and long-term partnerships. 

For more information, feel free to contact us on our website odixmedical.com or on Linkedin (https://www.linkedin.com/company/odixmedical/).